Search for a clinical trial
Other search option(s)
38 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
; Member of a ERN = 
National clinical trial(s)
AUSTRIA
WIEN
WIEN
RADIANT-4: A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
CANADA
Québec
MONTRÉAL
RADIANT 4: A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin - CA
Hôpital Royal Victoria - Royal Victoria Hospital
Clinical Research Program
GERMANY
Berlin
BERLIN
RADIANT-4: A randomized, double-blind, multicenter, phase III study of Everolimus (RAD001) plus best supportive care versus Placebo plus best supportive care in the treatment of patients with advanced Neuroendocrine tumor of gastrointestinal tract or lung origin - DE
Charité - Universitätsmedizin Berlin (CVK)
Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie (CVK)
GERMANY
Hessen
MARBURG
SONNET: Phase II, Multicentre, Open Label Study to Evaluate the Efficacy of the Combination of Lanreotide Autogel 120mg and Temozolomide in Patients With Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) G1/G2 - A Pilot-Study
Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg
Klinik für Visceral- Thorax- und Gefäßchirurgie
ITALY
LOMBARDIA
MILANO
A Phase II Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in Gastroenteropancreatic (GEP) and Thoracic Neuroendocrine Tumor (NET): The LOLA Trial
Fondazione IRCCS Istituto Nazionale dei Tumori
S.S. Oncologia Medica Gastroenterologica
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
KEYNOTE-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors - ES
Institution: Information not provided - ES
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
COMPETE: A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive, Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors (Phase 2) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs) - AT
Medizinische Universität Wien
Klinische Abteilung für Nuklearmedizin
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SCIROCCO: Sandostatin (Octreotide LAR) may lead to clinical improvement through receptor occupation optimisation. A prospective interventional trial of patients with neuro-endocrine tumors with carcinoid syndrome receiving octreotide LAR
Cliniques universitaires Saint-Luc - UCLouvain
Cliniques Universitaires Saint-Luc
FRANCE
ILE-DE-FRANCE
CLICHY
TERAVECT : A Randomized Phase III of Adjuvant Targeted Radionuclide Therapy With In111-Pentetreotide in Patients With Digestive Neuroendocrine Tumors After Complete Surgical Resection of Liver Metastases
CHU Paris Nord-Val de Seine - Hôpital Beaujon
Service de Pancréato-gastroentérologie
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE
COMPETE: Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients -GB
Institution: Information not provided - DE
GERMANY
Berlin
BERLIN
CLARINET: Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multi-centre study to assess the effect of deep subcutaneous injections of Lanreotide Autogel 120mg administered every 28 days on tumour progression free survival in patients with non-functioning Entero-pancreatic Endocrine Tumour
Charité - Universitätsmedizin Berlin (CVK)
Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie (CVK)
GERMANY
Thüringen
BAD BERKA
COMPETE: Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients -DE-
Zentralklinik Bad Berka GmbH
Zentrum für Neuroendokrine Tumoren Bad Berka
ITALY
EMILIA ROMAGNA
MELDOLA
LUCAS - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors: a Randomized Phase II Study
IRST - Istituto Scientifico Romagnolo per lo studio e la cura dei Tumori
UO Medicina Nucleare
SPAIN
Cataluña
BARCELONA
DUNE: A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with advanced neuroendocrine neoplasms of gastroenteropancreatic or lung origin - ES
Hospital Universitari Vall d'Hebron
Servicio de Oncología Médica
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
COMPETE: A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with [...], neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET) - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
NETTER-2: This is a multicenter, stratified, randomized, open-label comparator-controlled, Phase III study in patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs, diagnosed within 6 months prior to screening, comparing treatment with Lutathera [...] plus octreotide long-acting [...] - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
COMPOSE: A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate [...] Lutetium (177Lu) Edotreotide [...] in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin - ES
Institution: Information not provided - ES
SPAIN
Madrid
MADRID
NICE-NEC: A phase II study of Platinum-doublet chemotherapy in combination with nivolumab as first-line treatment, in subjects with unresectable, locally advanced or metastatic G3 Neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or of unknown (UK) origin - ES
Hospital Universitario 12 de Octubre
Servicio de Oncología Médica
SWITZERLAND
Suisse Alémanique
BASEL
An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) - CH
Universitätsspital Basel
Tumorzentrum
SWITZERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
COMPETE: Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients - CH
Institution: Information not provided - CH
UNITED KINGDOM
Greater London
LONDON
An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)GB
Royal Free Hospital
Department of Oncology
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
NETTER-1: A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours - AT
Institution: Information not provided - AT
FRANCE
BOURGOGNE-FRANCHE-COMTE
BESANÇON
EPICentro : Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors (Phase II)
CHU de Besançon - Hôpital Jean Minjoz
Service d'oncologie médicale
FRANCE
ILE-DE-FRANCE
VILLEJUIF
AcSé : Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types (Phase II)
CLCC Institut Gustave Roussy
Département d'Innovation Thérapeutique et d'Essais Précoces
GERMANY
Bayern
ERLANGEN
EVINEC: Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study - DE
Internistisches Zentrum des Universitätsklinikums Erlangen
Medizinische Klinik 1 - Gastroenterologie, Pneumologie und Endokrinologie
ITALY
EMILIA ROMAGNA
MELDOLA
A Phase II Study on Adjuvant Vaccination With Dendritic Cells Loaded With Autologous Tumor Homogenate in Resected Stage IV Rare Cancers: Head&Neck (H&N), Neuroendocrine Tumors (NET) and Soft Tissue Sarcoma (STS)
IRST - Istituto Scientifico Romagnolo per lo studio e la cura dei Tumori
Dipartimento di Oncologia ed ematologia clinica e sperimentale
ITALY
EMILIA ROMAGNA
MELDOLA
LUTHREE - Randomized Phase II Trial in sstr2 Positive Tumors to Optimize the Interval Between Cycles of PRRT With 177lu-dotatate Study
IRST - Istituto Scientifico Romagnolo per lo studio e la cura dei Tumori
UO Medicina Nucleare
ITALY
PUGLIA
SAN GIOVANNI ROTONDO
Bevacizumab in association with slow-relapsing Octreotide and Capecitabine in patients with well-differentiated neuroendocrine neoplasia and in advanced phase (Phase II)
Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza
U.O. di Oncologia
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued pasireotide treatment - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europe - ES
Institution: Information not provided - ES
NETHERLANDS
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
ITALY
LAZIO
ROMA
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
Multinational clinical trial(s)
UNITED STATES
New Jersey
RAHWAY
KEYNOTE 158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors
Merck, Sharp & Dohme Corp.
GERMANY
Berlin
ADDRESS: NOT PROVIDED - DE